Decreased expression of FBXW7 is correlated with poor prognosis in patients with esophageal squamous cell carcinoma

Naganawa,Yasuhiro; Ishiguro,Hideyuki; Kuwabara,Yoshiyuki; Kimura,Masahiro; Mitsui,Akira; Katada,Takeyasu; Tanaka,Tatsuya; Shiozaki,Midori; Fujii,Yoshitaka; Takeyama,Hiromitsu

doi:10.3892/etm.2010.115

Decreased expression of FBXW7 is correlated with poor prognosis in patients with esophageal squamous cell carcinoma

Authors:
- Yasuhiro Naganawa
- Hideyuki Ishiguro
- Yoshiyuki Kuwabara
- Masahiro Kimura
- Akira Mitsui
- Takeyasu Katada
- Tatsuya Tanaka
- Midori Shiozaki
- Yoshitaka Fujii
- Hiromitsu Takeyama
View Affiliations

Affiliations: Gastroenterological Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan, Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan
Published online on: July 12, 2010 https://doi.org/10.3892/etm.2010.115
Pages: 841-846

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

FBXW7 is a tumor suppressor gene that induces the degradation of positive cell-cycle regulators such as c-Myc, cyclin E, c-Jun and Notch. The loss of FBXW7 promotes cell-cycle progression and cell proliferation. In the present study, we investigated the relationship between FBXW7 expression and the clinicopathological characteristics of patients with esophageal squamous cell carcinoma (ESCC). The expression of FBXW7 was quantified by real-time reverse transcription polymerase chain reaction in 43 primary ESCCs and their paired normal esophageal mucosa in patients who had not received preoperative therapy. FBXW7 expression levels were significantly correlated with the progression of the cancer and with local invasiveness. In muscle-invasive tumor cases (T2-4), lymphatic invasive tumor cases and stage II-IV cases, FBXW7 expression levels were significantly decreased (P=0.0315, P=0.0336 and P=0.0289, respectively). Decreased expression of FBXW7 was correlated with poor prognosis (P=0.0255). In conclusion, this study examined the relationship between FBXW7 expression and tumor progression in ESCC. We suggest that FBXW7 is a molecular prognostic marker and can be used to elucidate the mechanism of carcinogenesis.

View Figures

View References

1.	Hu N, Huang J, Emmert-Buck MR, et al: Frequent inactivation of the tp53 gene in esophageal squamous cell carcinoma from a high-risk population in China. Clin Cancer Res. 7:883–891. 2001.PubMed/NCBI
2.	Audrezet MP, Robaszkiewicz M, Mercier B, et al: Tp53 gene mutation profile in esophageal squamous cell carcinomas. Cancer Res. 53:5745–5749. 1993.PubMed/NCBI
3.	Leung AC, Wong VC, Yang LC, et al: Frequent decreased expression of candidate tumor suppressor gene, DEC1, and its anchorage-independent growth properties and impact on global gene expression in esophageal carcinoma. Int J Cancer. 122:587–594. 2008. View Article : Google Scholar
4.	Yang L, Leung AC, Ko JM, et al: Tumor suppressive role of a 2.4 mb 9q33–q34 critical region and DEC1 in esophageal squamous cell carcinoma. Oncogene. 24:697–705. 2005.PubMed/NCBI
5.	Nishiwaki T, Daigo Y, Kawasoe T and Nakamura Y: Isolation and mutational analysis of a novel human cDNA, DEC1 (deleted in esophageal cancer 1), derived from the tumor suppressor locus in 9q32. Genes Chromosomes Cancer. 27:169–176. 2000. View Article : Google Scholar : PubMed/NCBI
6.	Park HL, Kim MS, Yamashita K, et al: DCC promoter hypermethylation in esophageal squamous cell carcinoma. Int J Cancer. 122:2498–2502. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Wang M, Lu R and Fang D: The possible role of loss of heterozygosity at APC, MCC and DCC genetic loci in esophageal carcinoma. Zhonghua Zhong Liu Za Zhi. 21:16–18. 1999.PubMed/NCBI
8.	Miyake S, Nagai K, Yoshino K, Oto M, Endo M and Yuasa Y: Point mutations and allelic deletion of tumor suppressor gene DCC in human esophageal squamous cell carcinomas and their relation to metastasis. Cancer Res. 54:3007–3010. 1994.PubMed/NCBI
9.	Seng TJ, Low JS, Li H, et al: The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene. 26:934–944. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Shiozaki H, Doki Y, Yamana H and Isono K: A multi-institutional study of immunohistochemical investigation for the roles of cyclin d1 and e-cadherin in superficial squamous cell carcinoma of the esophagus. J Surg Oncol. 79:166–173. 2002. View Article : Google Scholar
11.	Nagasawa S, Onda M, Sasajima K, et al: Cyclin d1 overexpression as a prognostic factor in patients with esophageal carcinoma. J Surg Oncol. 78:208–214. 2001. View Article : Google Scholar : PubMed/NCBI
12.	Sarbia M, Stahl M, Fink U, et al: Prognostic significance of cyclin d1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. Int J Cancer. 84:86–91. 1999. View Article : Google Scholar
13.	Souza RF, Garrigue-Antar L, Lei J, et al: Alterations of transforming growth factor-beta 1 receptor type II occur in ulcerative colitis-associated carcinomas, sporadic colorectal neoplasms, and esophageal carcinomas, but not in gastric neoplasms. Hum Cell. 9:229–236. 1996.
14.	Garrigue-Antar L, Souza RF, Vellucci VF, Meltzer SJ and Reiss M: Loss of transforming growth factor-beta type II receptor gene expression in primary human esophageal cancer. Lab Invest. 75:263–272. 1996.PubMed/NCBI
15.	Kawakami K, Brabender J, Lord RV, et al: Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst. 92:1805–1811. 2000. View Article : Google Scholar : PubMed/NCBI
16.	Rosato A, Pivetta M, Parenti A, et al: Survivin in esophageal cancer: an accurate prognostic marker for squamous cell carcinoma but not adenocarcinoma. Int J Cancer. 119:1717–1722. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Kato J, Kuwabara Y, Mitani M, et al: Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 95:92–95. 2001. View Article : Google Scholar : PubMed/NCBI
18.	Shimada Y, Imamura M, Shibagaki I, et al: Genetic alterations in patients with esophageal cancer with short- and long-term survival rates after curative esophagectomy. Ann Surg. 226:162–168. 1997. View Article : Google Scholar : PubMed/NCBI
19.	Reed SI: The ubiquitin-proteasome pathway in cell cycle control. Results Probl Cell Differ. 42:147–181. 2006. View Article : Google Scholar : PubMed/NCBI
20.	Nakayama KI and Nakayama K: Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 6:369–381. 2006. View Article : Google Scholar : PubMed/NCBI
21.	Akhoondi S, Sun D, von der Lehr N, et al: FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. 67:9006–9012. 2007. View Article : Google Scholar : PubMed/NCBI
22.	Fujii Y, Yada M, Nishiyama M, et al: FBXW7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation. Cancer Sci. 97:729–736. 2006. View Article : Google Scholar
23.	Welcker M, Orian A, Jin J, et al: The FBW7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci USA. 101:9085–9090. 2004. View Article : Google Scholar : PubMed/NCBI
24.	Hagedorn M, Delugin M, Abraldes I, et al: FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients. Cell Div. 2:92007. View Article : Google Scholar
25.	Koh MS, Ittmann M, Kadmon D, Thompson TC and Leach FS: CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther. 5:78–83. 2006. View Article : Google Scholar : PubMed/NCBI
26.	Iwatsuki M, Mimori K, Ishii H, et al: Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance. Int J Cancer. 126:1828–1837. 2009.
27.	Yokobori T, Mimori K, Iwatsuki M, et al: P53-altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res. 69:3788–3794. 2009.
28.	Mansour MR, Sulis ML, Duke V, et al: Prognostic implications of NOTCH1 and FBXW7 mutations in adults with t-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol. 27:4352–4356. 2009.PubMed/NCBI
29.	Baldus CD, Thibaut J, Goekbuget N, et al: Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute t-lymphoblastic leukemia. Haematologica. 94:1383–1390. 2009.PubMed/NCBI
30.	Welcker M and Clurman BE: FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 8:83–93. 2008. View Article : Google Scholar : PubMed/NCBI
31.	Welcker M, Orian A, Grim JE, Eisenman RN and Clurman BE: A nucleolar isoform of the FBW7 ubiquitin ligase regulates c-Myc and cell size. Curr Biol. 14:1852–1857. 2004. View Article : Google Scholar : PubMed/NCBI
32.	Mao JH, Perez-Losada J, Wu D, et al: FBXW7/CDC4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature. 432:775–779. 2004. View Article : Google Scholar
33.	Tsunematsu R: Cell cycle regulation by F-BOX protein FBXW7. Fukuoka Igaku Zasshi. 100:87–94. 2009.PubMed/NCBI
34.	Onoyama I and Nakayama K: Regulation of cell-cycle exit and g0-phase maintenance during differentiation by FBXW7. Tanpakushitsu Kakusan Koso. 53:1217–1224. 2008.PubMed/NCBI
35.	Onoyama I, Tsunematsu R, Matsumoto A, et al: Conditional inactivation of FBXW7 impairs cell-cycle exit during t cell differentiation and results in lymphomatogenesis. J Exp Med. 204:2875–2888. 2007.